CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 26, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present...

– Phase 2 Clinical Trial of KVD900 for On-Demand Oral Treatment of Hereditary Angioedema (HAE) Attacks Expected to Complete in Late 2019 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Data Expected in Q4 2019 – CAMBRIDGE, Mass....

– KVD900 Enrolling Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) with Data Expected in Late 2019 – – Enrollment Complete in KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) with Data Expected in H2 2019 – – Operations Funded into 2021 –...

  – Martin Edwards , MD, Elected as Chair – – Chair Richard H. Aldrich Resigns in Planned Transition – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 1, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development,...

– KVD900 Demonstrates Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity in a Phase 1 Study – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 4, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...

– KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein Activity and is Well Tolerated for Potential Use as On-Demand Treatment for HAE – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical...

– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 20, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the...

– Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 22, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has...